Press Releases

Pfizer Selects Cognizant for Business Process Outsourcing Solutions
Cognizant to Provide Clinical Data Management and Biometrics Services
Mumbai and Chennai, January 24, 2005

Mumbai and Chennai-January 24, 2005-As a part of an overall plan to strengthen its relationships with CROs, Pfizer Global Research and Development (PGRD), through its affiliate in India, and Cognizant Technology Solutions (NASDAQ: CTSH), a leading provider of IT services, today announced a multi-year relationship to provide high-end business process outsourcing solutions in the area of clinical data management and biometrics. This relationship allows Pfizer to leverage a rich talent pool while capturing the unique "cost-productivity" advantage India offers.

The Pfizer India Biometrics Division has been providing Data Capture, Data Management, Statistics and Programming services for its parent's Phase I, II, III global trials for seven years. It has been known for its on-time and quality delivery, with error rates that are among the lowest worldwide.

"Cognizant has extensive experience in life sciences including clinical trial study set-up and validation and data management that are compliant with international standards of good clinical practices (GCP) as defined by the FDA," said Hocine Sidi Said, Country Manager, Pfizer India, "That coupled with Cognizant's rich domain, technology, and business process expertise in the healthcare and life-sciences industry positions this new relationship with Pfizer for success."

"Cognizant's deep understanding of strategic pharmaceutical business processes and leadership position in the IT services segment of healthcare and life-sciences industry were key factors in Pfizer's decision to select Cognizant as the Company's preferred provider for their Business Process Outsourcing initiative," said Lakshmi Narayanan, president and CEO of Cognizant. "Our expertise in software and systems development and integration has provided Cognizant with a strong platform for developing a vertical BPO service to Pfizer."

About Pfizer :

Globally, Pfizer discovers, develops, manufactures, and markets leading prescription medicines for humans and animals and many of the world's best-known consumer brands. Our innovative, value-added products improve the quality of life of people around the world and help them enjoy longer, healthier, and more productive lives. The company has three business segments: health care, animal health and consumer health care. Our products are available in more than 150 countries.

Pfizer has been present in India since 1950.

About Cognizant Technology Solutions

Cognizant (NASDAQ: CTSH) is a leading provider of IT services. Focused on delivering strategic information technology solutions that address the complex business needs of its clients, Cognizant provides applications management, development, integration, and re-engineering, infrastructure management, business process outsourcing, and a number of related services such as enterprise consulting, technology architecture, program management and change management through its onsite/offshore outsourcing model.

Cognizant's more than 15,000 employees are committed to partnerships that sustain long-term, proven value for customers by delivering high-quality, cost-effective solutions through its development centers in India, and onsite client teams. Cognizant maintains P-CMM and SEI-CMM Level 5 assessments from an independent third-party assessor, was recently named Forbes' Best Small Company in America for the second consecutive year, and ranked as the top information technology company in BusinessWeek's Hot Growth Companies. Further information about Cognizant can be found at http://www.cognizant.com.

This press release includes statements which may constitute forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, the accuracy of which are necessarily subject to risks, uncertainties and assumptions as to future events that may not prove to be accurate. Factors that could cause actual results to differ materially from those expressed or implied include general economic conditions and the factors discussed in our most recent Form 10-K and other filings with the Securities and Exchange Commission. Cognizant undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.